Inflammation may be key in rare muscle disease

NCT ID NCT04694456

Completed Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This pilot study examined whether inflammation, measured by cytokines in the blood, plays a role in type 1 facioscapulohumeral muscular dystrophy (FSHD1). Researchers compared 20 FSHD1 patients with healthy controls to see if certain inflammatory markers are higher in the disease. Participants also underwent walking tests, muscle strength tests, and whole-body MRI scans to link inflammation with muscle damage. The goal is to understand the disease better and potentially identify new treatment targets.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could point toward inflammation as a target for future FSHD1 treatments.
What could go wrong: This is a small, early pilot study with only 20 patients. It measures biomarkers, not treatment effects, so results may not lead directly to therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

facioscapulohumeral muscular dystrophy 1 muscular dystrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MUSCULAR DYSTROPHIES

Contacts and locations

Locations

CHU de NICE

Nice, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.